pyridin-2-yl 3-oxo-androst-4-ene-17β-carbothioate | 146175-29-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: pyridin-2-yl 3-oxo-androst-4-ene-17β-carbothioate
• 英文别名: S-(2-pyridyl)-androst-4-ene-3-one-17β-thiocarboxylate；S-2-pyridyl 3-oxo-4-androstene-17β-thiocarboxylate；S-2-pyridyl 3-oxo-4-androstene-17beta-thiocarboxylate；S-pyridin-2-yl (8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carbothioate
• CAS: 146175-29-3
• 化学式: C₂₅H₃₁NO₂S
• 分子量: 409.593
• InChiKey: YQHJEBPJZIDKSM-RJBKZOIGSA-N

物化性质

• 沸点：
  565.9±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  72.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  pyridin-2-yl 3-oxo-androst-4-ene-17β-carbothioate 、 二苯甲胺 以the title compound was obtained in a yield of 85%的产率得到17β-(N-diphenylmethylcarbamoyl)androsta-4-ene-3-one
  参考文献：
  名称：

  Steroid derivatives

  摘要：

  发明的化合物##STR1##可用于生产具有5α-还原酶抑制活性的类固醇-17酰胺。

  公开号：

  US05698720A1
• 作为产物：
  描述：

  2,2'-二硫二吡啶 、 3-氧代-雄甾-4-烯-17beta-羧酸 在 三苯基膦 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 以0.87 g (71%)的产率得到pyridin-2-yl 3-oxo-androst-4-ene-17β-carbothioate
  参考文献：
  名称：

  17-.alpha.and 17-.beta.substituted acyl-3-carboxy-3,5-dienes and use in

  摘要：

  发明了17.alpha.和17.beta.-取代的酰基-3-羧基-3,5-二烯类类固醇合成化合物的类似物，含有这些化合物的药物组合物，以及使用这些化合物抑制类固醇5-.alpha.-还原酶的方法。还发明了制备这些化合物所用的中间体和过程。

  公开号：

  US05641765A1

文献信息

• Steroid derivatives for the treatment of prostatic hypertrophy their
  申请人：Sankyo Company, Limited

  公开号：US05536714A1

  公开（公告）日：1996-07-16

  The invention includes compounds of formula (I): ##STR1## in which R.sup.1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl; R.sup.2 is aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino; and R.sup.3 is carboxy or a group of formula --CONHSO.sub.2 R.sup.4 wherein R.sup.4 is alkyl; and pharmaceutically acceptable salts and esters of the compounds. The compounds have valuable 5.alpha.-reductase inhibitory activity and can thus be used for the treatment and prophylaxis of, inter alia, prostatic hypertrophy as well as other disorders arising from excess levels of 5.alpha.-dihydro-testosterone.

  该发明包括式(I)的化合物：##STR1##其中R.sup.1是氢，烷基，芳基取代的烷基或芳香杂环基取代的烷基；R.sup.2是芳基取代的烷基，芳香杂环基取代的烷基或二芳基胺基；R.sup.3是羧基或具有式--CONHSO.sub.2 R.sup.4的基团，其中R.sup.4是烷基；以及该化合物的药用可接受盐和酯。这些化合物具有有价值的5α-还原酶抑制活性，因此可用于治疗和预防前列腺肥大等疾病，以及由于5α-二氢睾酮水平过高而引起的其他疾病。
• Steroid derivatives
  申请人：Sankyo Company, Limited

  公开号：US05698720A1

  公开（公告）日：1997-12-16

  The invented compound ##STR1## is useful for the production of steroidal-17-amides that have 5.alpha.-reductase inhibitory activity.

  发明的化合物##STR1##可用于生产具有5α-还原酶抑制活性的类固醇-17酰胺。
• Steroid derivatives for the treatment of prostatic hypertrophy, their
  申请人：Sankyo Company, Limited

  公开号：US05760025A1

  公开（公告）日：1998-06-02

  Compounds of formula (I): ##STR1## \x9bwherein: R.sup.1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl; R.sup.2 is: aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino; and R.sup.3 is carboxy or a group of formula --CONHSO.sub.2 R.sup.4 wherein R.sup.4 is alkyl!; and pharmaceutically acceptable salts and esters thereof have valuable 5.alpha.-reductase inhibitory activity and can thus be used for the treatment and prophylaxis of, inter alia, prostatic hypertrophy as well as other disorders arising from excess levels of 5.alpha.-dihydrotestosterone.

  式(I)的化合物：##STR1## 其中：R.sup.1是氢、烷基、芳基取代的烷基或芳香族杂环取代的烷基；R.sup.2是芳基取代的烷基、芳香族杂环取代的烷基或二芳基氨基；R.sup.3是羧基或式--CONHSO.sub.2 R.sup.4中的基团，其中R.sup.4是烷基！；以及其药学上可接受的盐和酯具有有价值的5α-还原酶抑制活性，因此可用于治疗和预防前列腺肥大等由过量5α-二氢睾酮水平引起的其他疾病。
• Unsaturated 17beta-substituted 3-carboxy steroids
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0517047A1

  公开（公告）日：1992-12-09

  The present invention concerns steroidic 5α-reductase inhibitors having the following formula (I) wherein Y is oxygen or sulphur; R is a group: a) -OR₄, wherein R₄ is hydrogen or a C₁-C₆ alkyl group; b) wherein each of R₅ and R₆, independently, is hydrogen or a C₁-C₆ alkyl group; c) wherein R₇ is hydrogen or a C₁-C₆ alkyl group and W is a group: (i) wherein R₈ is a C₁-C₆ alkyl group, a C₅-C₆ cycloalkyl group, a C₆-C₉ cycloalkylalkyl group, a phenyl group or a benzyl group; or (ii) wherein R₉ is a C₁-C₆ alkyl group or a C₅-C₆ cycloalkyl group; or (iii) wherein R₅ and R₆ are as defined above; d) wherein each of R₁₀ and R₁₁ is, independently, hydrogen or a C₁-C₆ alkyl group or taken together with the nitrogen atom to which they are linked form a pentatomic or hexatomic saturated heteromonocyclic ring, optionally containing at least one additional heteroatom selected from oxygen and nitrogen, and n is an integer of 2 to 4; R₁ is hydrogen, a C₁-C₆ alkyl group, a C₅-C₆ cycloalkyl group, a C₆-C₉ cycloalkyalkyl group or an aryl group; each of R₂ and R₃ is, independently, selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₅-C₆ cycloalkyl, C₆-C₉ cycloalkylalkyl and aryl or R₂ and R₃, taken together with the nitrogen atom to which they are linked, form a pentatomic or hexatomic saturated heteromonocyclic ring, optionally containing at least one additional heteroatom selected from oxygen and nitrogen; and the symbol (----) represents a single or a double bond provided that when it is a double bond the hydrogen in the 5α position doesn't exist and the pharmaceutically acceptable salts thereof. In view of their 5-α reductase inhibiting activity the compounds of the invention can be useful for the treatment of androgen dependent conditions.

  本发明涉及具有下式（I）的类固醇 5α 还原酶抑制剂 其中 Y 是氧或硫； R 是一个基团： a) -OR₄，其中 R₄ 是氢或 C₁-C₆ 烷基； b) 其中 R₅ 和 R₆ 各自独立地为氢或 C₁-C₆ 烷基； c) 其中 R₇ 是氢或 C₁-C₆ 烷基，W 是一个基团： (i) 其中 R₈ 是 C₁-C₆ 烷基、C₅-C₆ 环烷基、C₆-C₉ 环烷基、苯基或苄基；或 (ii) 其中 R𠢙 是 C₁-C₆ 烷基或 C₅-C₆ 环烷基；或 (iii) 其中 R₅ 和 R₆ 如上文所定义； d) 其中 R₁₀和 R₁₁ 各自独立为氢或 C₁-C₆ 烷基，或与它们相连的氮原子一起形成五原子或六原子饱和杂环，可选地含有至少一个选自氧和氮的额外杂原子，且 n 为 2 至 4 的整数； R₁ 是氢、C₁-C₆ 烷基、C₅-C₆ 环烷基、C₆-C₉ 环烷基或芳基； R₂ 和 R₃ 各自独立地选自氢、C₁-C₆ 烷基、C₅-C₆ 环烷基、C₆-C₉ 环烷基和芳基或 R₂ 和 R₃ 所组成的组、与它们相连的氮原子一起形成五原子或六原子饱和杂环，可选择含有至少一个选自氧和氮的额外杂原子；符号(----)代表单键或双键，条件是当它是双键时，5α 位的氢不存在，以及它们的药学上可接受的盐。 鉴于其 5-α 还原酶抑制活性，本发明化合物可用于治疗雄激素依赖性疾病。
• Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0567271A2

  公开（公告）日：1993-10-27

  Compounds of formula (I): [wherein : R1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl ; R2 is: aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino; and R3 is carboxy or a group of formula -CONHS02 R4 wherein R4 is alkyl] ; and pharmaceutically acceptable salts and esters thereof have valuable 5α-reductase inhibitory activity and can thus be used for the treatment and prophylaxis of, inter alia, prostatic hypertrophy as well as other disorders arising from excess levels of 5α-dihydro-testosterone.

  式(I)化合物： [其中 ：R1 是氢、烷基、芳基取代的烷基或芳香杂环取代的烷基；R2 是：芳基取代的烷基、芳香杂环取代的烷基或二芳基氨基；以及 R3 是羧基或式 -CONHS02 R4 的基团，其中 R4 是烷基]；及其药学上可接受的盐类和酯类具有重要的 5α 还原酶抑制活性，因此可用于治疗和预防前列腺肥大以及因 5α 二氢睾酮水平过高而引起的其他疾病。